1788-08-5

Basic information

• Product Name: 4-Ethynylbenzenesulfonamide
• Synonyms: Benzenesulfonamide, 4-ethynyl- (9CI);4-ethynylbenzenesulfonamide;4-ethynylbenzene-1-sulfonaMide;BenzenesulfonaMide, 4-ethynyl-;4-Ethynybenzenesulfonamide
• CAS NO: 1788-08-5
• Molecular Formula: C₈H₇NO₂S
• Molecular Weight: 181.21
• Product Categories: SULFONAMIDE
• Mol File: 1788-08-5.mol
• Article Data: 15

Chemical Properties

• Melting Point: 178.0 to 182.0 °C
• Boiling Point: 338.2 °C at 760 mmHg
• Flash Point: 158.4 °C
• Appearance: /
• Density: 1.38 g/cm³
• Refractive Index: 1.623
• Storage Temp.: 2-8°C
• PKA: 9.88±0.10(Predicted)
• CAS DataBase Reference: 4-Ethynylbenzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Ethynylbenzenesulfonamide(1788-08-5)
• EPA Substance Registry System: 4-Ethynylbenzenesulfonamide(1788-08-5)

Safety Data

• Hazardous Substances Data: 1788-08-5(Hazardous Substances Data)

Usage

General Description

4-Ethynylbenzenesulfonamide is a chemical compound with the molecular formula C8H7NO2S. It is a sulfonamide derivative with an ethynyl group attached to the benzene ring. 4-Ethynylbenzenesulfonamide is commonly used as a building block in organic synthesis and pharmaceutical research. It has been studied for its potential medicinal properties, including anti-cancer and anti-inflammatory effects. 4-Ethynylbenzenesulfonamide is also used as a reagent in chemical reactions and as a precursor for the synthesis of various organic compounds. Overall, 4-Ethynylbenzenesulfonamide is a versatile and important chemical with numerous applications in the field of chemistry and medicine.

InChI:InChI=1/C8H7NO2S/c1-2-7-3-5-8(6-4-7)12(9,10)11/h1,3-6H,(H2,9,10,11)

Upstream product

• 775331-26-5 4-((trimethylsilyl)ethynyl)benzenesulfonamide 
• 701-34-8 4-bromo-benzenesulfonic acid amide 
• 1066-54-2 trimethylsilylacetylene 
• 98-58-8 4-bromobenzenesulfonyl chloride 
• 138-36-3 p-bromobenzene sulfonic acid 
• 1056474-58-8 (Z)-4-(2-bromovinyl)benzenesulfonamide 

Relevant articles and documents

INSULIN CONJUGATES

The present invention relates to a conjugate comprising a sulfonamide of formula (I) and an active pharmaceutical ingredient such as an insulin analog comprising at least one mutation relative to the parent insulin, wherein the insulin analog comprises a mutation at position B16 which is substituted with a hydrophobic amino acid and/or a mutation at position B25 which is substituted with a hydrophobic amino acid. The present invention further relates to a sulfonamide of formula (A). Moreover, the present invention relates to an insulin analog comprising at least one mutation relative to the parent insulin.

Novel valdecoxib derivatives by ruthenium?II)-promoted 1, 3-dipolar cycloaddition of nitrile oxides with alkynes - Synthesis and COX-2 inhibition activity

Novel valdecoxib-based cyclooxygenase-2 inhibitors were synthesized in one step via 1, 3-dipolar cycloaddition of nitrile oxides with a series of eleven aryl alkynes, six of them described for the first time. Application of Ru?II)-catalysis leads preferab

RAFAMYCIN ANALOGS AND METHODS FOR MAKING SAME

A semi-synthetic rapamycin analog with a triazole moiety or a pharmaceutically acceptable salt or prodrug thereof, is a broad-spectrum cytostatic agent and a mTOR inhibitor, and is useful in the treatment of various cancers, or tumors in organs such as kidney, liver, breast, head and neck, lung, prostate, and restenosis in coronary arteries, peripheral arteries, and arteries in the brain, immune and autoimmune diseases. Also disclosed are fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method of inhibiting cancer, fungal growth, restenosois, post-transplant tissue rejection, and immune and autoimmune disease in a mammal. One particular preferred application of such triazole-moiety containing rapamycin analog is in treating renal carcinoma, lung cancer, colon cancer, and breast cancers wherein potency of the drug, its half-life, tissue distribution properties, and its pharmacokinetic properties including bioavailability through oral and intravenous routes are essential to the clinical outcomes.